The COVID-19 Clinical Research Center is a standalone research facility for the conduct of phase 1-3 clinical trials to find effective treatments for SARS-CoV-2-positive study participants. The CCRC offers the opportunity for collaboration by virologists, immunologists, epidemiologist, translational and physician scientists to apply their expertise to determine safe and effective therapies in partnership with health care providers, research institutes, and the biotech/pharmaceutical industry.
It will take a collaborative effort of researchers, scientists, health care providers and study participants to work together in stopping this pandemic. As a treatment and prevention resource, the Clinical Research Center will incorporate a diverse population of study participants in novel intervention and therapeutic trials to help in the local and international effort to deliver cures faster.
The Clinical Research Center offers an opportunity for participants interested in emerging treatments and interventions that are safely administered and evaluated outside of a traditional hospital setting. The Center is seeking volunteer participants to gather insights from a diverse population within the community that are SARS-CoV-2-positive, both asymptomatic or mildly symptomatic.
The CCRC facility is a stand-alone building on the Fred Hutch campus. It is designed to support active COVID-19 research participants outside a hospital setting that prioritizes participant and staff safety.
We have addressed questions about the clinical studies and the safe conduct practices at the CCRC, as well as the most commonly asked questions about volunteer study participation.
The COVID-19 Clinical Research Center aims to collaborate with research partners who are developing and testing novel interventions, to treat infection early and effectively. We seek area health care colleagues who share our drive to innovate, collaborate, and save lives to both identify participants and conduct clinical trials. The COVID-19 pandemic is placing a great burden on health care systems. We aim to lessen this burden by treating infection early after the development of symptoms for these reasons:
Dr. Rachel Bender lgnacio serves as the Medical Director of the CCRC. In addition to overseeing a team of on-site clinical and support staff, she'll also be responsible for ensuring that the trials are conducted safely and with best clinical and scientific practices. She has overseen the scientific and operational processes for clinical trials related to COVID-19 since the start of the pandemic. Dr. Bender Ignacio is an assistant professor in the Division of Allergy & Infectious Diseases in the University of Washington Department of Medicine and an associate in the Hutch's Vaccine and Infectious Disease Division.
Every dollar helps our scientists reduce the threat of the novel coronavirus.
Entrance A:
820 Minor Ave N.
Seattle, WA 98109
Directions
Entrance B:
1205 Aloha St.
Seattle, WA 98109
Directions